Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

News

February 1, 2023
PRESS RELEASE: On January 26, 2023, a new research paper was published in Oncotarget, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).” continue reading »

Oncotarget | Intraventricular immunovirotherapy; a translational step forward

Oncotarget

January 26, 2023
PRESS RELEASE: On January 12, 2023, a new research perspective was published in Oncotarget, entitled, “Intraventricular immunovirotherapy; a translational step forward.” continue reading »

Oncotarget | The chromatographic constitution of andiroba oil and its healing effects…

News

January 24, 2023
PRESS RELEASE: On January 12, 2023, Oncotarget published a new research paper: “The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option.” continue reading »

Researchers Identify New Drug Candidates to Treat DLST+ Tumors

Oncotarget

January 19, 2023
The increased expression of DLST has recently been associated with increased tumor aggression and a poor prognosis in neuroblastoma and triple-negative breast cancer. continue reading »

Oncotarget | Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001

News

January 17, 2023
PRESS RELEASE: On January 12, 2023, Oncotarget published a new research paper, entitled, “Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.” continue reading »